Stock CGEM CULLINAN THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Cullinan Therapeutics, Inc.

Equities

CGEM

US2300311063

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-17 pm EDT 		5-day change 1st Jan Change
23.17 USD -2.69% Intraday chart for Cullinan Therapeutics, Inc. -12.80% +127.38%
May. 15 Cullinan Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
May. 15 Cullinan Therapeutics, Inc. Announces Board Changes CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Cullinan Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
GL
Cullinan Therapeutics, Inc. Announces Board Changes
CI
Cullinan Therapeutics Insider Sold Shares Worth $1,796,676, According to a Recent SEC Filing
MT
Cullinan Therapeutics Appoints Mary Kay Fenton as CFO
MT
Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer
GL
Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer
AQ
Cullinan Therapeutics, Inc Appoints Mary Kay Fenton as Chief Financial Officer
CI
Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024
GL
Cullinan Oncology : Therapeutics Corporate Update
PU
Transcript : Cullinan Oncology, Inc. - Special Call
Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases
GL
Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases
AQ
Cullinan Oncology, Inc. Announces Important Updates About Its Plan to Expand into Autoimmune Diseases, the Scientific Rationale for Developing CLN-978 in Autoimmune Diseases
CI
Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement
GL
Cullinan Oncology, Inc. announced that it expects to receive $280.000024 million in funding from a group of investors
CI
Cullinan Oncology, Inc.(NasdaqGS:CGEM) added to S&P Biotechnology Select Industry Index
CI
Cullinan Oncology Finance Chief Jeffrey Trigilio to Leave
MT
Cullinan Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CGEM Stock
  4. News Cullinan Therapeutics, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW